About Verrow Pharmaceuticals
Verrow Pharmaceuticals is a Healthcare company based in Lenexa (United States) founded in 2006, and was acquired by Ligand Pharmaceuticals in January 2018. Kidney-safe X-ray contrast agents are developed through US drug reformulation. The company was acqui-hired. Its focus areas include Life Sciences, Nephrology, Drugs and Metabolic Diseases. Its competitors include Unicycive, Peloton Therapeutics and Angion Biomedica; 3 of its 3 listed competitors have raised funding.
Company details
Verrow Pharmaceuticals was founded in 2006 and is headquartered in Lenexa, United States. Operations center on drug reformulation within the pharmaceutical sector. A kidney-safe X-ray contrast agent named Veropaque was patented in Europe in 2014 to mitigate risks of acute kidney injury. In 2010, a 244,000 grant was received under the US governments Qualifying Therapeutic Discovery Project.
- Headquarters Lenexa, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website verrow.com
- Social LinkedIn
- Acquired by Ligand Pharmaceuticals (Jan 2018)
- Investors
- Acquired byLigand Pharmaceuticals
(Jan 2018)
Investors in Verrow Pharmaceuticals
Verrow Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical drugs are manufactured and developed in the United States. | 1987 | ligand.com | San Diego, United States |
Investor details for Verrow Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Verrow Pharmaceuticals
2 dated milestones of Verrow Pharmaceuticals across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Verrow Pharmaceuticals is founded.
- Exit Acquired by Ligand Pharmaceuticals.
Competitors of Verrow Pharmaceuticals
Verrow Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Unicycive, Peloton Therapeutics and Angion Biomedica.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| unicycive.com | 2016 | San Francisco, United States | $1.55M | 12 | Small molecule therapies for kidney diseases are developed. | |
| pelotontherapeutics.com | 2010 | Dallas, United States | $242.6M | 62 | Small molecule therapeutics for kidney cancer are developed. | |
| angion.com | 1998 | United States | $73.95M | 71 | Organ restoration therapies for renal diseases are developed. |
Detailed competitors of Verrow Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Verrow Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Verrow Pharmaceuticals
Verrow Pharmaceuticals was founded in 2006.
Verrow Pharmaceuticals is headquartered in Lenexa, United States. It is registered at Lenexa, Kansas, United States.
Verrow Pharmaceuticals was founded in 2006 and is headquartered in Lenexa, United States. Operations center on drug reformulation within the pharmaceutical sector. A kidney-safe X-ray contrast agent named Veropaque was patented in Europe in 2014 to mitigate risks of acute kidney injury. In 2010, a 244,000 grant was received under the US governments Qualifying Therapeutic Discovery Project.
Verrow Pharmaceuticals's top competitors include Unicycive, Peloton Therapeutics and Angion Biomedica.
Verrow Pharmaceuticals has 1 investor. Key investors include Ligand Pharmaceuticals.
Yes. Verrow Pharmaceuticals was acquired by Ligand Pharmaceuticals in January 2018.